Activated leukocyte cell adhesion molecule/CD166 as a non-invasive biomarker in women with breast cancer

IF 2.3 Q2 PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH

Clinical Epidemiology and Global Health Pub Date : 2025-03-12 DOI:10.1016/j.cegh.2025.101974

Vemareddy Hemalatha , Shabna Roupal , Vanitharani Nagasubramanian , Bhawna Dev , S.D. Rajendran

{"title":"Activated leukocyte cell adhesion molecule/CD166 as a non-invasive biomarker in women with breast cancer","authors":"Vemareddy Hemalatha , Shabna Roupal , Vanitharani Nagasubramanian , Bhawna Dev , S.D. Rajendran","doi":"10.1016/j.cegh.2025.101974","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>ALCAM, as a non-invasive diagnostic biomarker, has the potential to revolutionize breast cancer screening by enabling early intervention and, ultimately, improving patient survival rates. This study investigated the ALCAM concentration and its diagnostic accuracy at the early stages of breast cancer (T1/T2, M0, N0).</div></div><div><h3>Methodology</h3><div>A total of 81 early stage breast cancer patients confirmed by histopathology and 81 healthy female volunteers whose breast ultrasound or mammogram were normal were included in the study. Blood, saliva, and urine samples were collected from all the included participants, centrifuged at 3000 RPM for 10 min, and the supernatant was stored at −80 °C until analyzed for ALCAM expression by using the Human ALCAM ELISA Kit.</div></div><div><h3>Results</h3><div>Receiver Operating Curves (ROC) were used to evaluate the diagnostic performance of the ALCAM biomarker in serum, saliva, and urine and were 0.947, 0.996, and 0.947, respectively. The sensitivity, specificity, and cut-off values of ALCAM expression in serum (87.7, 84, and ≥49.5), saliva (95.5, 96.3, and ≥52.5), and urine (88.89, 89.19, and ≥55) were interpreted.</div></div><div><h3>Conclusion</h3><div>ALCAM can be used to detect early breast cancers, showing better noninvasive diagnostic values. The study findings infer that ALCAM may represent a biomarker for breast cancer, which may have potential utility as a diagnostic tool as per the sensitivity and specificity values obtained.</div></div>","PeriodicalId":46404,"journal":{"name":"Clinical Epidemiology and Global Health","volume":"33 ","pages":"Article 101974"},"PeriodicalIF":2.3000,"publicationDate":"2025-03-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Epidemiology and Global Health","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2213398425000636","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH","Score":null,"Total":0}

引用次数: 0

Abstract

Background

ALCAM, as a non-invasive diagnostic biomarker, has the potential to revolutionize breast cancer screening by enabling early intervention and, ultimately, improving patient survival rates. This study investigated the ALCAM concentration and its diagnostic accuracy at the early stages of breast cancer (T1/T2, M0, N0).

Methodology

A total of 81 early stage breast cancer patients confirmed by histopathology and 81 healthy female volunteers whose breast ultrasound or mammogram were normal were included in the study. Blood, saliva, and urine samples were collected from all the included participants, centrifuged at 3000 RPM for 10 min, and the supernatant was stored at −80 °C until analyzed for ALCAM expression by using the Human ALCAM ELISA Kit.

Results

Receiver Operating Curves (ROC) were used to evaluate the diagnostic performance of the ALCAM biomarker in serum, saliva, and urine and were 0.947, 0.996, and 0.947, respectively. The sensitivity, specificity, and cut-off values of ALCAM expression in serum (87.7, 84, and ≥49.5), saliva (95.5, 96.3, and ≥52.5), and urine (88.89, 89.19, and ≥55) were interpreted.

Conclusion

ALCAM can be used to detect early breast cancers, showing better noninvasive diagnostic values. The study findings infer that ALCAM may represent a biomarker for breast cancer, which may have potential utility as a diagnostic tool as per the sensitivity and specificity values obtained.

查看原文本刊更多论文

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinical Epidemiology and Global Health PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH-

CiteScore

4.60

自引率

7.70%

发文量

218

审稿时长

66 days

期刊介绍： Clinical Epidemiology and Global Health (CEGH) is a multidisciplinary journal and it is published four times (March, June, September, December) a year. The mandate of CEGH is to promote articles on clinical epidemiology with focus on developing countries in the context of global health. We also accept articles from other countries. It publishes original research work across all disciplines of medicine and allied sciences, related to clinical epidemiology and global health. The journal publishes Original articles, Review articles, Evidence Summaries, Letters to the Editor. All articles published in CEGH are peer-reviewed and published online for immediate access and citation.